Press

Press

2024-04-29 11:23 Acarix receives order from the first freestanding Emergency Room in the US
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the CADScor System has been added to the diagnostic tools available at Tucson...
2024-04-23 15:00 Acarix AB’s Annual Report 2023 Regulatory
Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2023 is available as a pdf on the company's...
2024-04-23 15:00 Acarix AB’s Årsredovisning 2023 Regulatory
Acarix, ledande inom avancerad akustikbaserad hjärtdiagnostik, meddelar idag att årsredovisning för 2023 finns tillgänglig som pdf på bolagets hemsida...
2024-04-11 15:30 NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB Regulatory
The shareholders of Acarix AB, reg. no. 559009-0667 (the "Company"), are hereby invited to the annual general meeting on Tuesday 14 May 2024 at 10:00 CET...
2024-04-11 15:30 KALLELSE TILL ÅRSSTÄMMA I ACARIX AB Regulatory
Aktieägarna i Acarix AB, org.nr 559009-0667 ("Bolaget"), kallas härmed till årsstämma tisdagen den 14 maj 2024 kl. 10:00 i Baker McKenzie Advokatbyrås...
2024-04-11 09:38 Acarix announces the initiation of the first US-based clinical workflow evaluation study
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to collect real-world data...
2024-04-11 09:38 Acarix inleder klinisk utvärderingsstudie hos University of California
Acarix, ledande inom avancerad akustikbaserad hjärtdiagnostik, tillkännager idag uppstarten av den första kliniska studien i USA i syfte att samla in...
2024-04-11 08:00 Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review Regulatory MAR
Acarix, a leader in advanced acoustic- and algorithm-based cardiac diagnostics, announces the adoption of a new innovative usage-based business model in...
2024-04-11 08:00 Acarix antar ny tillväxtfokuserad affärsmodell och ger en uppdatering av strategiska och finansiella mål Regulatory MAR
Acarix, ledande aktör inom akustik- och algoritmbaserad hjärtdiagnostik, tillkännager idag införandet av en ny innovativ användarbaserad affärsmodell...
2024-04-08 14:15 Ny hälsoekonomisk analys presenterad på ACC styrker kostnadseffektiviteten i Acarix CADScor System
Acarix, ledande aktör inom akustiskbaserad hjärtdiagnostik, tillkännager idag resultaten från en presentation på årets American College of Cardiology...
2024-04-08 14:15 New Health Economic Analysis Presented at ACC Highlights The Acarix CADScor System’s Cost-Effectiveness
Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (ACC) poster presentation...
2024-04-05 13:48 Acarix has submitted application for cross-trading at OTCQB in the US
New York, New York, April 5, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics announces the submission of an application for cross-trading...
2024-04-05 13:48 Acarix lämnar in ansökan om handel av bolagets aktie på OTCQB-marknaden i USA
New York, New York, 5 april 2024 – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, meddelar idag inlämnandet av en ansökan om...
2024-03-20 19:51 Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2) Regulatory
The Board of directors of Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise period for warrants of series 2024:U1 (TO2)...
2024-03-20 19:51 Acarix offentliggör utfall av utnyttjande av teckningsoptioner av serie 2024:U1 (TO2) Regulatory
Styrelsen för Acarix AB (”Acarix” eller ”Bolaget”) offentliggör idag utfallet av utnyttjandeperioden för teckningsoptioner av serie 2024:U1...
2024-03-19 09:12 Acarix erhåller avsiktsförklaringar avseende nyttjande av teckningsoptioner av serie TO 2
Acarix AB (”Acarix” eller ”Bolaget”) har mottagit muntliga avsiktsförklaringar avseende nyttjande av Teckningsoptionerna av serie TO 2 (”Teckningsoptionerna”)...
2024-03-19 09:12 Acarix receives declarations of intent to exercise warrants of series TO 2
Acarix AB ("Acarix" or the "Company") has received oral declarations of intent to exercise Warrants of series TO 2 (the "Warrants") from a number of major...
2024-03-15 15:57 CEO purchases shares in Acarix
New York, New York, March 15, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Aamir Mahmood, recently appointed...
2024-03-15 15:57 VD köper aktier i Acarix
New York, New York, 15 mars 2024 – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, meddelar att Aamir Mahmood, nyligen utsedd VD...
2024-03-06 08:00 The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today Regulatory
The exercise period for the warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix AB ("Acarix" or the "Company") rights issue...
2024-03-06 08:00 Idag inleds utnyttjandeperioden för Acarix teckningsoptioner av serie 2024:U1 (TO2) Regulatory
Utnyttjandeperioden för de teckningsoptioner av serie 2024:U1 (TO2) (”Teckningsoptioner”) som emitterades i samband med Acarix AB:s (”Acarix”...
2024-02-21 17:03 Announcement from Acarix's extra general meeting Regulatory
The extra general meeting of Acarix AB (the "Company") was held today on 21 February 2024 and the following resolution was passed by the meeting.
2024-02-21 17:03 Kommuniké från extra bolagsstämma i Acarix Regulatory
Extra bolagsstämma i Acarix AB ("Bolaget") hölls idag den 21 februari 2024 varvid aktieägarna fattade följande beslut.
2024-02-15 12:51 Acarix strengthens US Advisory Board with three industry leaders
New York, New York, February 15, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors...
2024-02-15 12:51 Acarix expanderar USA-baserat Advisory Board med tre nya rådgivare
New York, New York, 15 februari 2024 – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, har utnämnt tre nya rådgivare till sitt...
2024-02-15 08:00 Acarix AB (publ) publicerar Bokslutskommuniké 2023 Regulatory
Fokus mot USA och hållbar tillväxt
2024-02-15 08:00 Acarix AB (publ) publishes Year-End Report 2023 Regulatory
Embarking on a new journey with focus on sustainable growth
2024-02-14 10:15 Invitation to presentation of Acarix´s fourth quarter report
Acarix will publish its fourth quarter results on Thursday 15 February 2024 at 08.00 am (CEST). A live webcast will be held at 15.00 (CEST) the same day...
2024-02-14 10:15 Inbjudan till presentation av Acarix delårsrapport för fjärde kvartalet 2023
Acarix publicerar sin rapport för fjärde kvartalet på torsdag den 15 februari 2024 kl 08.00. En direktsänd webbsändning kommer att hållas kl 15.00...
2024-02-02 10:10 Acarix CADScor System now listed on US Federal Supply Schedule
Acarix, a leader in advanced acoustic and algorithm based cardiac diagnostic devices today announces that its CADScor System has been added to the US Federal...
PreviousNext

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.